Revenue Calculator
How much could TCD bring to your practice?
Enter your estimated weekly TCD patients to see projected Medicare revenue — at $0 upfront cost. Most patients receive more than one study per visit.
TCD patients per week
Estimated annual revenue
—
retained in-practice
Multiple studies per patient: Every patient receives a complete intracranial study (93886). About 70% also receive an emboli detection study without injection (93892), and 30% receive one with injection (93893) — meaning most patients generate 2 studies, and some generate 3.
Studies per year
—
Monthly revenue
—
avg. per month
Annual revenue
—
retained in-practice
Upfront cost
$0
equipment & staffing
| CPT | Description | % of patients | Studies/mo | Monthly | Annual |
|---|---|---|---|---|---|
| 93886 | Complete intracranial | 100% | — | — | — |
| 93892 | Emboli, no injection | 70% | — | — | — |
| 93893 | Emboli, with injection | 30% | — | — | — |
| Total | — | — | — | ||
2026 Medicare reimbursement rates (non-facility)
93886 Complete TCD — $270.21
93892 Emboli w/o injection — $318.65
93893 Emboli w/ injection — $395.13
Rates calculated using 2026 Medicare Physician Fee Schedule conversion factor of $33.401 applied to 2023 AAN-published RVU values (93886: 8.09 RVUs; 93892: 9.54 RVUs; 93893: 11.83 RVUs). Study mix reflects average TCD patient population distribution. Commercial payer rates (BCBS, UHC, Aetna, Cigna) are typically higher. Actual reimbursement varies by payer, geography, and contract. Contact Vohanix for a practice-specific analysis.